Kyverna Therapeutics
(NASDAQ) KYTX
Kyverna Therapeutics Financials at a Glance
Market Cap
$536.10M
Revenue (TTM)
$0.00
Net Income (TTM)
$161.31M
EPS (TTM)
$-3.66
P/E Ratio
-2.43
Dividend
$0.00
Beta (Volatility)
1.93 (High)
Dividend
$0.00
Beta (Volatility)
1.93 (High)
Price
$8.86
Volume
757,061.231
Open
$8.57
Price
$8.86
Volume
757,061.231
Open
$8.57
Previous Close
$8.87
Daily Range
$8.50 - $9.18
52-Week Range
$1.78 - $13.67
Dividend
$0.00
Beta (Volatility)
1.93 (High)
Price
$8.86
Volume
757,061.231
Open
$8.57
Previous Close
$8.87
Daily Range
$8.50 - $9.18
52-Week Range
$1.78 - $13.67
KYTX News
KYTX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Kyverna Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
130
CEO
Warner Biddle
Website
www.kyvernatx.comHeadquarters
Emeryville, CA 94608, US
KYTX Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-65%
Return on Capital
-66%
Return on Assets
-55%
Earnings Yield
-41.15%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$536.10M
Shares Outstanding
60.44M
Volume
757.06K
Short Interest
0.00%
Avg. Volume
743.98K
Financials (TTM)
Gross Profit
$1.80M
Operating Income
$169.83M
EBITDA
$167.38M
Operating Cash Flow
$153.71M
Capital Expenditure
$5.00K
Free Cash Flow
$153.72M
Cash & ST Invst.
$279.25M
Total Debt
$29.03M
Kyverna Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$368.00K
+34.6%
Gross Margin
0.00%
N/A
Market Cap
$536.10M
N/A
Market Cap/Employee
$4.79M
N/A
Employees
112
N/A
Net Income
$37.80M
-0.8%
EBITDA
$38.91M
-5.5%
Quarterly Fundamentals
Net Cash
$250.22M
-9.9%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$25.06M
+482.6%
Short Term Debt
$3.97M
+0.7%
Return on Assets
-54.90%
N/A
Return on Invested Capital
-65.99%
N/A
Free Cash Flow
$33.52M
+10.8%
Operating Cash Flow
$33.53M
+9.5%